<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338815</url>
  </required_header>
  <id_info>
    <org_study_id>376-19</org_study_id>
    <nct_id>NCT04338815</nct_id>
  </id_info>
  <brief_title>Exoskeleton Variability Optimization</brief_title>
  <official_title>Exoskeleton Variability Optimization for Reducing Gait Variability for Patients With Peripheral Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate a potentially faster and more clinically feasible method to&#xD;
      optimize exoskeletons in pilot tests in healthy in preparation for patients with peripheral&#xD;
      artery disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to convergence</measure>
    <time_frame>10 minutes</time_frame>
    <description>We will determine when the estimated optimal exoskeleton settings vary less than 10%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak extension timing</measure>
    <time_frame>20 seconds</time_frame>
    <description>Timing of peak extension moment of exoskeleton (% stride cycle)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak flexion timing</measure>
    <time_frame>20 seconds</time_frame>
    <description>Timing of peak flexion moment of exoskeleton (% stride cycle)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Largest Lyupunov exponent</measure>
    <time_frame>20 seconds</time_frame>
    <description>Largest Lyapunov exponent of lower limb kinematics</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Determine optimal assistance pattern</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Determine effects on endurance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exoskeleton optimization</intervention_name>
    <description>Participants will walk 10 times 1 minute while an optimization algorithm changes the assistance profile of an exoskeleton.</description>
    <arm_group_label>Determine optimal assistance pattern</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endurance evaluation</intervention_name>
    <description>Participants will walk 2 times at a speed of 1 meter per second until the participant indicates claudication or a maximum duration of 6 minutes.</description>
    <arm_group_label>Determine effects on endurance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written consent&#xD;
&#xD;
          -  Chronic claudication history&#xD;
&#xD;
          -  Ankle-brachial index &lt; 0.90 at rest&#xD;
&#xD;
          -  Stable blood pressure, lipides, and diabetes for &gt; 6 weeks&#xD;
&#xD;
          -  Ability to walk on a treadmill for multiple five-minute spans.&#xD;
&#xD;
          -  Ability to fit in exoskeleton: waist circumference 78 to 92 centimeters, thigh&#xD;
             circumference 48 to 60 centimeters, minimal thigh length 28 centimeters.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rest pain or tissue loss due to PAD (Fontaine stage III and IV).&#xD;
&#xD;
          -  Foot ulceration.&#xD;
&#xD;
          -  Acute lower extremity event secondary to thromboembolic disease or acute trauma&#xD;
&#xD;
          -  Walking capacity limited by diseases which are unrelated to PAD such as:&#xD;
&#xD;
        Neurological disorders, musculoskeletal disorders (arthritis, scoliosis, stroke, spinal&#xD;
        injury, etc.), a history of ankle instability, knee injury, diagnosed joint laxity, lower&#xD;
        limb injury, surgery within the past 12 months, joint replacement, pulmonary disease or&#xD;
        breathing disorders, cardiovascular disease, or vestibular disorder. This will be&#xD;
        determined by verbal questioning from research personnel by verbally asking about&#xD;
        conditions limiting their walking, whether subjects are taking medications for those&#xD;
        conditions, and physicians' recommendations about limiting activity.&#xD;
&#xD;
          -  Acute injury or pain in their lower extremity or current illness.&#xD;
&#xD;
          -  Inability to follow visual cues due to blindness.&#xD;
&#xD;
          -  Inability to follow auditory cues due to deafness.&#xD;
&#xD;
          -  Women who are currently pregnant are excluded for safety reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Malcolm</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Malcolm, PhD.</last_name>
    <phone>6174871148</phone>
    <email>pmalcolm@unomaha.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Nebraska Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68182</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Malcolm, PhD</last_name>
      <phone>402-554-4182</phone>
      <email>pmalcolm@unomaha.edu</email>
    </contact>
    <investigator>
      <last_name>Philippe Malcolm, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Philippe Malcolm</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Exoskeleton</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

